GAITHERSBURG, MD — April 18, 2023 — MoneyShow Newswire — BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, announced its Founder and CEO, Vin Singh, will participate in a panel discussion at the MoneyShow, taking place at the Paris Las Vegas Hotel & Casino April 24-26, 2023. 

Investors will have two opportunities to attend the panel discussion "Innovators in a Dynamic Tech Environment - A Perfect Fit for Your Portfolio," hosted Monday, April 24, at 3:10 p.m. PT and again on Tuesday, April 25, at 1:15 p.m. PT.

"I look forward to the opportunity to discuss BullFrog AI's vision for a new era of precision medicine and how we are using machine learning to transform the drug development process," said Singh. "Thanks to our recent Nasdaq IPO, we are now operating from a significantly stronger financial foundation that we believe will accelerate our progress and accomplishments in the quarters ahead. We are excited to share our progress and plans for the future with attendees at the show."

For 40 years, MoneyShow has maintained market dominance in connecting self-directed investors and active traders with world-class financial experts. The very basis for MoneyShow’s existence is to deliver to this targeted audience truly elite-caliber advice, actionable recommendations, new opportunities, and profitable strategies from a wide network of knowledgeable, experienced experts.

Register now to meet BullFrog AI's CEO in person.

About BullFrog AI

BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.

For more information visit BullFrog AI at: